BioCatalystWatch
OMERWorkspace / OMER / OverviewCompany library
Price
Market cap
Next catalystBegin enrollment in Q1 2027, following the required additional nonclinical workOMS527 — planned inpatient cocaine-use-disorder trial · Trial initiationCompany source ↗
Cash

Chart & Events

Candle interval

Core Clinical

narsoplimab

MASP-2

Upcoming / outlook

OMS527

PDE7

PreINDP1P3FilingApproved
Upcoming / outlook

narsoplimab

MASP-2

Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

OMS527

PDE7

PreINDP1P3FilingApproved
Upcoming / outlook

narsoplimab

MASP-2

Upcoming / outlook

narsoplimab

MASP-2

Upcoming / outlook

Other pipelines

OMS805

PreINDP2P3FilingApproved
Upcoming / outlook

OMS527

PDE7

conserved microbial surface antigens × complement-cleaving enzyme

OMS527

PDE7

PreINDP1P2P3FilingApproved

Approved / commercial

History / paused

MASP-2

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

OMER PR & News

OMER SEC archive